Summary of Arcturus Therapeutics KOL Presentation on ARCT-810 Phase II Interim Data for OTC Deficiency Company Overview - **Company**: Arcturus Therapeutics - **Headquarters**: San Diego - **Focus**: mRNA medicines, specifically targeting rare liver diseases like ornithine transcarbamylase (OTC) deficiency [5][6] Industry Context - **Industry**: Biotechnology, specifically in the development of mRNA therapeutics for rare diseases - **Condition**: OTC deficiency is the most common urea cycle disorder with significant unmet medical needs [6][7] Key Points from the Presentation 1. **ARCT-810 Overview**: - ARCT-810 is an mRNA therapeutic designed to replace dysfunctional OTC enzymes, improving urea cycle activity, detoxifying ammonia, and potentially eliminating the need for liver transplants [6][7][8] - It utilizes Arcturus' proprietary lunar delivery platform for effective delivery to hepatocytes [7] 2. **Regulatory Designations**: - ARCT-810 has received multiple designations: orphan drug designation, orphan medicinal product designation, fast track designation, and rare pediatric disease designation [8] 3. **Phase II Study Design**: - Two Phase II studies were conducted: one in the US and one in Europe, focusing on safety, tolerability, and biomarker assessments [11][12] - The US study enrolled patients with more severe disease, while the European study included patients with stable disease [12] 4. **Biomarker Results**: - **Plasma Glutamine**: - In the European study, mean glutamine levels decreased from high to normal during treatment and began to rise again after four weeks post-treatment [13][14] - In the US study, glutamine levels normalized after three doses and remained normal for approximately twenty days [14] - **Ureagenesis Function**: - The new N15 assay showed significant increases in relative ureagenesis function (RUF) post-treatment, with a mean increase of 14.7% [16][17] - Two subjects achieved RUF levels above 50%, indicating clinically meaningful improvements [17] - **Ammonia Levels**: - Ammonia levels remained stable and within normal ranges after treatment, supporting the favorable glutamine and ureagenesis data [18] 5. **Safety Profile**: - The safety database included 40 participants, indicating that ARCT-810 was generally safe and well-tolerated [19] - No serious infusion-related reactions were reported, and adverse events were manageable [19][20] 6. **Next Steps**: - Arcturus plans to complete the ongoing Phase II US study and engage with regulatory agencies for a multi-biomarker driven pivotal trial [68][69] Additional Insights - **Clinical Implications**: - The KOLs emphasized the importance of normalizing diet and reducing the need for ammonia scavengers as key success metrics for OTC therapies [78][80] - mRNA therapies are viewed as a potential alternative to liver transplants, especially for severe cases [100][101] - **Comparison with Other Therapies**: - ARCT-810 is positioned as a more effective solution compared to existing ammonia scavengers, which do not restore urea cycle function [87][88] Conclusion - The interim data for ARCT-810 demonstrates promising results in reducing glutamine levels and improving urea cycle function, with a favorable safety profile. The company is poised to advance its clinical development and regulatory strategy to address the significant unmet needs in OTC deficiency treatment [67][68]

Defense Industry Trends - Increased venture funding for defense startups driven by ongoing conflicts, potentially leading to further innovation [1] - Expectation of a durable trend of increased spending in the defense sector, possibly a continuation of the Cold War or the beginning of World War II [2][3] - NATO member countries are committing to spending 5% of their GDP on defense [3] - Cultural aversion in Silicon Valley towards supporting American defense is diminishing, making the sector more attractive for investment [4] - Market pull for the entire defense supply chain, including startups, is increasing [4][5] Procurement Challenges & Solutions - Both increased overall defense spending and a reallocation towards more efficient, higher-tech defense companies are anticipated [6] - Lengthy procurement cycles (NATO: ~17 years, US DoD: ~7+ years) pose a significant challenge for startups [7] - Efforts are underway to reduce and rationalize procurement cycles to enable startups to participate effectively [8] - Bureaucratic processes and a lack of financial incentives in the military hinder the adoption of innovative solutions from startups [11][12][13][14] Venture Capital & Private Equity Concerns - Illiquidity and lack of distributed capital (DPI) are major crises facing VC and private equity [17][18] - The concept of "private forever" is alarming because the industry depends on long-term liquidity to pay back distributions [20] - Extension of fund lifecycles (from 8 years to 12-15 years) and compression of fees are indicators of the liquidity crisis [21]

Oliver Rodzianko is the Founder and Chief Executive Officer of Invictus Origin, a pioneering high-alpha investment management firm launched in May 2025, dedicated to becoming a globally recognized, actively managed fund. Invictus Origin is developing innovative portfolio strategies, notably through its flagship Nasdaq High-Alpha Black Swan Portfolio, strategically designed to sustainably outperform the Nasdaq-100. Distinctively, this portfolio maintains approximately 20% in strategic cash reserves, providin ...

Trump's talking about getting rid of Jerome Powell, which means the administration wants lower rates, which means a liquidity cycle is forthcoming, which means liquidity cycles equal much higher asset appreciation. You know that first of all, we should talk about that next week. We should talk about that.Donnie says it well. Don't get distracted. Make a plan and stick to it long term. That's a great place to end it. ...

Market Trends & Analysis - Bitcoin rebounded following de-escalation in the Middle East, driven by institutional buys and macro shifts in the U S economy [1] - Altseason may be delayed due to BTC dominance and shrinking liquidity [1] - Key macro signals include US PCE, trade deals, interest rate outlook & ETF flows [1] Cryptocurrency Highlights - XRP's legal saga has ended, sparking IPO buzz [1] - SEI experienced a 100% pump, fueled by ETF speculation, state adoption, and institutional inflows [1] - Cardano's Midnight tokenomics, VeChain & Jupiter updates are noted [1] Regulatory & Institutional Actions - Barclays has banned crypto buys [1] - Tokenized stocks have been approved [1] Promotional Offers - Binance offers a 20% trading fee discount and a $600 bonus [1] - Ledger provides deals including $10 of free BTC and discounts on new products [1] - Arkham offers a 50% trading fee discount [1]

【2025年上半年A股呈结构化慢牛，私募量化指增收益领跑，下半年多策略有配置机会】2025年上半 年，A股呈现结构化慢牛行情，私募量化指增收益领跑其他策略。展望下半年，仍看好指增策略全年收 益，短期对中性策略持观望态度，市场波动率有望放大，CTA趋势和套利策略存在配置机会。 半年度 私募策略表现上，证券类私募业绩亮眼，量化策略领跑。从大类资产看，延续一季度排名，股票策略＞ 宏观策略＞CTA策略＞债券策略。其中，指数增强策略最优，平均收益达14.20%。"指增+期权"复合结 构产品是创新型策略，适用于慢牛市和结构性行情，头部量化私募已优先布局。 指增/中性策略方面， Beta端关注6月政策窗口期及量能变化，小微盘有上行空间但需警惕踩踏风险；端超额环境偏暖；对冲 端股指期货深贴水不利产品建仓。下半年仍看好指增策略配置价值，建议用"红利+小微盘"指增抵御风 险；对中性策略暂时观望，股指深贴水影响有限。 CTA策略上，今年上半年中证商品期货指数下挫 0.16%，呈震荡走势，4月上旬因关税政策冲击快速下行。五大细分板块走势分化，贵金属板块上涨， 黑色建材和能源化工板块下行。CTA因子收益分化，持仓因子最强，波动率因子最 ...

Equities are the Alt Coins of this crypto cycle ...

Group 1 - The central theme of the articles published in the first half of the year is change, particularly in the real estate sector [1] - The focus includes various asset classes, with a specific emphasis on the troubled office market [1]

The first half of 2025 is almost over and boy, it's been really good so far.I've already achieved more than the goals I set myself before the year started, in every way.A while back I wrote about how your personal crypto journey always moves in cycles, you'll go through long phases where nothing happens.And then, from time to time, there will be a few months where you experience the perfect storm.InfoFi and everything related to it since Kaito introduced yaps in December 2024 has been this perfect storm for ...

Let's talk about the main reasons why #ALT season has not happened this market cycle so far, and what things might need to happen in order for #ALT season to happen again. Into The Cryptoverse Premium SALE: https://intothecryptoverse.com Into The Cryptoverse Newsletter: https://newsletter.intothecryptoverse.com/ LIFETIME OPTION: https://intothecryptoverse.com/product/subscription-to-the-premium-list-lifetime/ Alternative Option: https://www.patreon.com/intothecryptoverse Merch: https://store.intothecryptove ...